


**Product Name** : Evatanepag  
**Cat. No.** : PC-27072  
**CAS No.** : 223488-57-1  
**Molecular Formula** : C<sub>25</sub>H<sub>28</sub>N<sub>2</sub>O<sub>5</sub>S  
**Molecular Weight** : 468.57  
**Target** : Prostaglandin Receptor  
**Solubility** : 10 mM in DMSO



## Biological Activity

Evatanepag (CP-533536, CP-533,536) is a highly selective and potent functional EP2 receptor agonist with high affinity to rat EP2 receptor (IC<sub>50</sub>=50 nM), is >50-fold more selective over EP4 receptor subtype.

Evatanepag (CP-533536) also shows high selectivity over other prostanoid receptors, including those for prostaglandin D2, prostaglandin F2a, prostacyclin, and thromboxane.

Evatanepag induces intracellular cAMP levels in HEK-293 cells stably transfected with the EP2 receptor with IC<sub>50</sub> of 5 nM.

Evatanepag induces changes in total bone area (TBA), total bone mineral content (BMC), and total bone mineral density (BMD) in the rat local injection model.

Evatanepag has the ability to heal canine long bone segmental and fracture model defects without the objectionable side effects of PGE2.

## References

Zhou M, et al. An EP2 receptor-selective prostaglandin E2 agonist induces bone healing. Proc Natl Acad Sci U S A. 2003 May 27;100(11):6736-40.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com